caffeine and mrs 1754
caffeine has been researched along with mrs 1754 in 7 studies
Research
Studies (7)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Jacobson, KA; Kim, HS; Kim, SA; Linden, J; Marshall, MA; Melman, N; Müller, CE | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Bertarelli, DC; Borrmann, T; Florin, NC; Hinz, S; Li, W; Müller, CE; Scheiff, AB | 1 |
| Cheng, F; Liu, G; Tang, Y; Xu, Z | 1 |
| Azuaje, J; Carbajales, C; Crespo, A; El Maatougui, A; Escalante, L; García-Mera, X; González-Gómez, M; Gutiérrez-de-Terán, H; Miguez, G; Sotelo, E | 1 |
| Delbeck, M; Gerisch, M; Härter, M; Kalthof, B; Kast, R; Lindner, N; Lustig, K; Meibom, D; Schulz, S | 1 |
| Gaba, S; Gupta, GD; Monga, V; Patel, R; Saini, A; Singh, G | 1 |
Reviews
1 review(s) available for caffeine and mrs 1754
| Article | Year |
|---|---|
Adenosine receptor antagonists: Recent advances and therapeutic perspective.
Topics: Dose-Response Relationship, Drug; Humans; Molecular Structure; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1; Structure-Activity Relationship | 2022 |
Other Studies
6 other study(ies) available for caffeine and mrs 1754
| Article | Year |
|---|---|
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.
Topics: Animals; Binding, Competitive; Cell Line; Cloning, Molecular; Humans; Ligands; Purinergic P1 Receptor Antagonists; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2B; Receptors, Purinergic P1; Recombinant Proteins; Structure-Activity Relationship; Xanthines | 2002 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity.
Topics: Adenosine A2 Receptor Antagonists; Animals; Drug Design; Humans; Kinetics; Ligands; Mice; Protein Binding; Radioligand Assay; Rats; Receptor, Adenosine A2B; Xanthines | 2009 |
Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods.
Topics: Adenosine A2 Receptor Antagonists; Amino Acid Sequence; Drug Discovery; Humans; Ligands; Models, Molecular; Molecular Conformation; Molecular Sequence Data; Protein Binding; Receptor, Adenosine A2B; Reproducibility of Results; Sequence Homology, Amino Acid | 2010 |
Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes.
Topics: Adenosine A2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Discovery; Humans; Models, Molecular; Molecular Structure; Pyrimidinones; Receptor, Adenosine A2B; Structure-Activity Relationship | 2016 |
Novel non-xanthine antagonist of the A
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; High-Throughput Screening Assays; Pulmonary Fibrosis; Receptor, Adenosine A2B; Signal Transduction; Structure-Activity Relationship; Uracil | 2019 |